Nogales Bruce 4

Accession 0001225208-10-019876

CIK 0001405197other

Filed

Aug 25, 8:00 PM ET

Accepted

Aug 26, 5:56 PM ET

Size

23.3 KB

Accession

0001225208-10-019876

Form 4

Period: 2010-08-25

Sr. VP & GM, Plasma Resources

Transactions

Exercise/Conversion
Common Stock
2010-08-25$11.00/sh+4,834$53,174→ 47,993 total
Exercise/Conversion
Common Stock
2010-08-26$1.39/sh+21,267$29,561→ 39,760 total
Sale
Common Stock
2010-08-26$22.00/sh−37,005$813,936→ 5,921 total
Exercise/Conversion
Options (right to buy)
2010-08-25$11.00/sh−4,834$53,174→ 3,166 total
Exercise: $11.00From: 2008-04-01Exp: 2017-07-09→ Common Stock (4,834 underlying)
Exercise/Conversion
Options (right to buy)
2010-08-25$1.39/sh−18,733$26,039→ 86,707 total
Exercise: $1.39Exp: 2015-11-10→ Common Stock (18,733 underlying)
Exercise/Conversion
Options (right to buy)
2010-08-26$1.39/sh−21,267$29,561→ 65,440 total
Exercise: $1.39Exp: 2015-11-10→ Common Stock (21,267 underlying)
Sale
Common Stock
2010-08-25$21.92/sh−29,500$646,726→ 18,493 total
Exercise/Conversion
Common Stock
2010-08-26$11.00/sh+3,166$34,826→ 42,926 total
Exercise/Conversion
Options (right to buy)
2010-08-26$11.00/sh−3,166$34,826→ 0 total
Exercise: $11.00From: 2008-04-01Exp: 2017-07-09→ Common Stock (3,166 underlying)
Exercise/Conversion
Common Stock
2010-08-25$1.39/sh+18,733$26,039→ 43,159 total

Holdings

Options (right to buy)
Exercise: $19.00Exp: 2019-09-30→ Common Stock (11,755 underlying)
11,755

Footnotes (6)

[F1]The transaction reported was effected purusant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2010.
[F2]The number of shares reported includes restricted share units representing the right to receive 5,921 shares of the Issuers common stock that will vest in three equal annual installments beginning April 1, 2011, as detailed in a restricted share unit award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.
[F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.81 to $21.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and footnote 4 that follows.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.95 to $22.05, inclusive.
[F5]The option is fully vested and immediately exercisable.
[F6]Option will vest in three equal annual installments beginning April 1, 2011, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.

Documents

1 file

Talecris Biotherapeutics Holdings Corp.

CIK 0001405197

Entity typeother